The mifepristone ruling by the United States Court of Appeals for the Fifth Circuit on 16 August is by no means the last word on access to medication abortion, but it could end up being a definitive one nonetheless.
The appeals court ruling concluded that the REMS modifications that FDA enacted in 2016 – which raised the gestational...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?